Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study

• ClinicalTrials.gov Identifier: NCT01174810
• Recruitment Status: Unknown
• First Posted: August 4, 2010
• Last Update Posted: March 23, 2012
• Sponsor: University College, London
• Information provided by: University College, London

Tracking Information

• First Submitted Date: August 2, 2010
• First Posted Date: August 4, 2010
• Last Update Posted Date: March 23, 2012
• Study Start Date: July 2010
• Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: August 3, 2010): Change from baseline to 12 months & 14 months between patients on active Exenatide treatment and PD controls in respect of their UPDRS-off-medication motor subscore.
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: August 3, 2010)

Adverse event profile among patients treated with Exenatide compared with matched PD controls. Change from baseline to 12 months/ 14 months between patients on active treatment and PD controls in respect of list given below

• the UPDRS on medication motor subscore
• the UPDRS ADL subscore
• dyskinesia rating scale
• timed motor tests
• the Mattis Dementia rating scale
• the Montgomery & Asberg Depression rating scale
• the PDQ39
• the EQ-5D
• the NMS Quest
• the SCOPA Sleep scale
• the SCOPA AUT scale
• the Smell Identification test
• DAT (SPECT) scan appearances.

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study
• Official Title: An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.

Brief Summary

Exenatide is a licensed, safe and effective treatment for patients with Diabetes mellitus. Laboratory work has shown strong, reproducible evidence that this drug has beneficial "disease modifying" effects when given to animals with a range of experimental models of Parkinson's disease (PD). This project aims to make an initial evaluation of possible benefits of Exenatide among patients with moderate symptoms of PD. The drug will be given as a twice daily 10microgram injection under the skin in a similar way to one of the conventional "symptomatic" treatments for PD (Apomorphine).

Forty patients with moderate symptoms of PD will be recruited and randomised to receive Exenatide injections twice daily, or to act as controls in this open label trial. Detailed assessments will be made of all patients at baseline and periodically for a total of 14 months. The primary outcome measure will be the change between baseline and follow up, in the severity of a validated PD assessment scale (the UPDRS part 3 motor score) after an overnight period free of conventional PD medication. Secondary measures will include adverse event reports, self completed questionnaires, and blood test results. Aside from these assessments, all patients will continue their regular PD medications throughout the trial with adjustments made only according to clinical need.

In a subgroup of patients (n=10), brain scans that assess the severity of PD, will be performed at both baseline and follow up to help understand possible mechanisms of action of Exenatide.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Parkinson's Disease

Intervention

Drug: Exenatide

Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months

Other Names:

• Byetta
• Exendin-4

Study Arms

• No Intervention: Control
• Experimental: Exenatide
  Intervention: Drug: Exenatide

• Publications *: Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013 Jun;123(6):2730-6. doi: 10.1172/JCI68295.

Recruitment Information

• Recruitment Status: Unknown status
• Estimated Enrollment (submitted: August 3, 2010): 40
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: March 2013
• Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Diagnosis of Idiopathic Parkinson's disease of moderate severity- equivalent to Hoehn/ Yahr stage 2 to 2.5 (Bilateral symptoms but still physically independent).

Male or female. Female patients to be post menopausal (defined as 12 months of spontaneous amenorrhoea or 6 months spontaneous amenorrhoea with FSH levels greater than 40mIU/ml), surgically sterilised (post hysterectomy and/or oophorectomy). Male patients with female partners that have child bearing potential must use adequate contraception (condoms +/-spermicidal gel/foam) throughout the duration of the trial period.

• Age 45-70 years
• Disease onset after age 40 years
• Disease duration > 5 years
• On L-dopa treatment. Patient must be on oral L-dopa treatment - with or without dopamine agonist including Apomorphine, MAO-B inhibitor, COMT inhibitor, Amantadine, Beta blocker, anticholinergic treatment History of wearing off phenomena- duration of action of single dose of L-dopa < 6 hours Stable PD medication for preceding 3 months- i.e. no change in medication type or dose.
• UPDRS motor off medication score >15
• L-dopa responsiveness. Defined as >33% improvement in UPDRS motor off medication score following L-dopa challenge
• Able to give informed consent
• Able to comply with trial protocol and willing to attend necessary clinic visits off medication.

Exclusion Criteria:

• Diagnosis or suspicion of other cause for parkinsonism including Vascular parkinsonism, post traumatic parkinsonism, drug or toxin induced parkinsonism, or other neurodegenerative condition including Multiple System Atrophy, Progressive Supranuclear Palsy, Huntington's disease, Wilson's disease, Pantothenate kinase Neurodegeneration (PKAN), Alzheimer's disease, Creutzfeld Jacob disease.
• Known abnormality on CT or MRI brain imaging considered to be causing symptoms or signs of neurological dysfunction, or considered likely to compromise compliance with trial protocol.

Concurrent dementia defined by a score lower than 120 on the Mattis Dementia Rating Scale.

• Concurrent severe depression defined by a score greater than 16 on the MADRS Exposure to neuroleptic drugs within 6 months prior to baseline assessment Prior intracerebral surgical intervention for Parkinson's disease including Deep Brain stimulation, lesional surgery, growth factor administration, gene therapy or cell transplant
• Already actively participating in a trial of a device, drug or surgical treatment for Parkinson's disease, or trial participation within previous 30 days.
• Type 1 Diabetes mellitus
• Type 2 Diabetes mellitus on insulin treatment
• End stage renal disease or severely impaired renal function with creatinine clearance <30ml/min
• History of severe cardiac disease (Angina, Myocardial infarction or cardiac surgery in preceding 2 years)
• History of pancreatitis
• History of alcoholism
• Severe gastrointestinal disease including gastroparesis
• Ongoing treatment with sulphonylurea
• Females that are pregnant or breast feeding or of child bearing potential.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 45 Years to 70 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT01174810
• Other Study ID Numbers: 09/0391; 2009-018137-37 ( EudraCT Number )
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Dr Thomas Foltynie, UCL
• Original Responsible Party: Same as current
• Current Study Sponsor: University College, London
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: University College, London
• Verification Date: March 2012